Navigation Links
Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
Date:8/3/2009

at include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the SEC on May 11, 2009, as well as other filings by the company with the SEC.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Announces Pricing of Public Offering of Common Stock
2. Micromet Announces Public Offering of Common Stock
3. Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
4. Micromet Added to Russell 3000 Index
5. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
6. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
7. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
8. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
9. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
10. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
11. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
(Date:1/14/2014)... 2014 During the 1600’s through the 1800’s ... Doctor’s Plague.” In this time period, doctors did not know ... times, to the death of vulnerable patients. In the same ... they may be unwittingly transmitting herpes viruses to their patients. ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... IP Ownership into Discussion , ... Reston, VA (PRWEB) ... of data integrity solutions, announced today that is has joined the ... protection provider of its kind within the alliance. , , ...
... Ipilimumab to be Presented -PRINCETON, N.J., April 29 ... that the following clinical abstracts for ipilimumab in melanoma ... antibody for cancer treatment, have been selected to be ... the American Society of Clinical Oncology, being held May ...
... of Net Product Sales; Quarter Highlighted by Nearly $7 Million ... Pa., April 29 ViroPharma Incorporated (Nasdaq: VPHM ... ended March 31, 2009., , ... income of $11.5 million, and GAAP net loss of $59.2 ...
Cached Biology Technology:Surety, LLC Joins Microsoft BioIT Alliance 2Surety, LLC Joins Microsoft BioIT Alliance 3Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 2Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 3Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 4ViroPharma Incorporated Reports First Quarter 2009 Financial Results 2ViroPharma Incorporated Reports First Quarter 2009 Financial Results 3ViroPharma Incorporated Reports First Quarter 2009 Financial Results 4ViroPharma Incorporated Reports First Quarter 2009 Financial Results 5ViroPharma Incorporated Reports First Quarter 2009 Financial Results 6ViroPharma Incorporated Reports First Quarter 2009 Financial Results 7ViroPharma Incorporated Reports First Quarter 2009 Financial Results 8ViroPharma Incorporated Reports First Quarter 2009 Financial Results 9ViroPharma Incorporated Reports First Quarter 2009 Financial Results 10ViroPharma Incorporated Reports First Quarter 2009 Financial Results 11ViroPharma Incorporated Reports First Quarter 2009 Financial Results 12ViroPharma Incorporated Reports First Quarter 2009 Financial Results 13ViroPharma Incorporated Reports First Quarter 2009 Financial Results 14ViroPharma Incorporated Reports First Quarter 2009 Financial Results 15
(Date:4/23/2014)... allergies and other chronic inflammatory disorders among people of ... their reduced exposure to the microbes that thrive in ... The article, published in the journal Clinical & ... centers who have less access to green spaces may ... caused by immune system dysfunction. , When our immune ...
(Date:4/23/2014)... French and German . ... and other mammals, the difference between sexes depends on one single ... in males, where the two sexual chromosomes are X and Y, ... responsible for all the morphological and physiological differences between males and ... very long time ago, the X and Y were identical, until ...
(Date:4/23/2014)... Like a hungry diner ripping open a dinner roll, ... must tear open a hydrogen molecule. Now researchers have ... the two halves of its hydrogen feast. The view ... make the catalyst work better for alternative energy uses. ... shown precisely where the hydrogen halves end up in ...
Breaking Biology News(10 mins):Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3Male or female? 2Male or female? 3Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4
... to play a pivotal role in the inception of Darwin’s ... of their significance when he collected them during his voyage ... to predict the impact the vast amount of marine microbial ... by J. Craig Venter, Ph.D., and his team ?will have ...
... option for treating atrial fibrillation, a common irregular heart ... University School of Medicine in St. Louis have developed ... a complex surgical procedure that has had the best ... simplified procedure is termed Cox-maze IV, and the surgeons ...
... have large outbreaks of Ebola virus killed tens of ... Observations published in the May issue of The American ... amplified by Ebola transmission between ape social groups. The ... the devastating impact of Ebola on wild apes. ...
Cached Biology News:Darwin's famous finches and Venter's marine microbes 2Darwin's famous finches and Venter's marine microbes 3Darwin's famous finches and Venter's marine microbes 4Darwin's famous finches and Venter's marine microbes 5Surgeons develop simpler way to cure atrial fibrillation 2Ebola outbreaks killing thousands of gorillas and chimpanzees 2
The Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 6 microcentrifuge tubes....
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by the lipoxygenation of linoleic acid ... detected in atherosclerotic plaques, as an esterified component ...
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
...
Biology Products: